28. 全身性アミロイドーシス Disease details / Clinical trials / Drug dev / DR info

124I-AT03
   Attralus, Inc.
      2021   Phase 1   NCT05201911   United States
124I-labeled monoclonal antibody MU 11-1f4
   University of Tennessee
      2008   Phase 1   NCT01409148   United States
      2008   Phase 1   NCT00807872   United States
124I-P5+14 injection
   University of Tennessee Graduate School of Medicine
      2018   Phase 1/Phase 2   NCT03678259   United States
2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid
   John L. Berk
      2010   -   EUCTR2006-001066-16-GB   Italy;Sweden;United Kingdom
   John L. Berk, M.D.
      2007   -   EUCTR2006-001066-16-SE   Italy;Sweden;United Kingdom
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat
   FoldRx Pharmaceuticals, Inc.
      2007   Phase 2;Phase 3   EUCTR2006-002792-41-GB   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Ltd.
      2009   Phase 3   EUCTR2009-011535-12-FR   France;Germany;Italy;Portugal;Sweden
2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate
   FoldRx Pharmaceuticals Limited
      2009   -   EUCTR2008-001262-87-DE   France;Germany;Portugal;Sweden
      2008   -   EUCTR2008-001262-87-SE   France;Germany;Portugal;Sweden
      2007   -   EUCTR2006-002792-41-DE   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-SE   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001262-87-PT   France;Germany;Portugal;Sweden
      2008   Phase 2;Phase 3   EUCTR2008-001262-87-FR   France;Germany;Portugal;Sweden
      2006   -   EUCTR2006-002792-41-PT   Germany;Portugal;Spain;Sweden;United Kingdom
3-(3-(3,5-dimethyl-1H-pyrazol-4-YL)propoxy)-4-fluorobenzoic acid
   Eidos Therapeutics, Inc
      2020   Phase 3   EUCTR2018-004670-10-IT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
   Eidos Therapeutics, Inc.
      2020   Phase 3   EUCTR2018-004670-10-PT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-HU   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-FR   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-DE   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-BG   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      -   Phase 3   EUCTR2018-004670-10-NL   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey
4'-IODO-4'-deoxydoxorubicin
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00030381   United States
      1999   Phase 2   NCT00003853   Italy;United States
A01ac02
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
Aciclin
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Aciclovir
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Acoramidis
   Eidos Therapeutics, a BridgeBio company
      2021   Phase 3   NCT04882735   -
Acyclovir
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
AG10
   Eidos Therapeutics, a BridgeBio company
      2020   Phase 3   NCT04418024   Canada;Spain;United States
AG10 HCL
   Eidos Therapeutics, Inc
      2020   Phase 3   EUCTR2018-004670-10-IT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
   Eidos Therapeutics, Inc.
      2020   Phase 3   EUCTR2018-004670-10-PT   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-HU   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-FR   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-DE   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      2020   Phase 3   EUCTR2018-004670-10-BG   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Taiwan;Turkey
      -   Phase 3   EUCTR2018-004670-10-NL   Argentina;Brazil;Bulgaria;Canada;France;Germany;Hungary;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;Turkey
Alkeran
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
   European Myeloma Network
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
Allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
ALN-51547
   ALNYLAM PHARMACEUTICALS, INC.
      2015   Phase 3   EUCTR2014-003835-20-IT   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-005333-49-GB   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-SE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-ES   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-DE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-BE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-003835-20-GB   Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
ALN-65492
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
ALN-TTR02
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
ALN-ttrsc
   ALNYLAM PHARMACEUTICALS, INC.
      2015   Phase 3   EUCTR2014-003835-20-IT   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-005333-49-GB   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-SE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-ES   Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-DE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-BE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-003835-20-GB   Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
ALN-ttrsc02
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224769   Asia except Japan;Europe;Japan;North America;Oceania;South America
Amifostine trihydrate
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
Anakinra
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2006-001927-20-IT   Italy
ANTI-CD38 monoclonal antibody
   University of Turin, Italy
      2022   -   NCT06571864   Italy
Antiviral therapy
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Aprotinin
   National Center for Global Health and Medicine
      2010   -   JPRN-UMIN000012319   Japan
AT-02
   Attralus, Inc.
      2022   Phase 1   NCT05521022   Australia;United States
AT02
   Attralus, Inc.
      2023   Phase 2   NCT05951049   Australia;United Kingdom;United States
Autologous bone marrow transplantation
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
Autologous hematopoietic stem cell transplantation
   Mayo Clinic
      2005   Phase 3   NCT00477971   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Autologous peripheral blood stem cell transplantation
   Boston Medical Center
      2000   Phase 2   NCT00075621   United States
Autologous stem cell transplant
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Autologous stem cell transplantation
   Boston Medical Center
      2001   Phase 2   NCT00075608   United States
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
   University Hospital, Limoges
      2000   Phase 3   NCT00344526   France
Autologous-autologous tandem hematopoietic stem cell transplantation
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
Bassado - 100 MG compresse 10 compresse
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2018   Phase 2   EUCTR2017-002210-31-IT   Germany;Italy
Belantamab mafodotin
   European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-NL   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-GR   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-FR   France;Germany;Greece;Italy;Netherlands;United Kingdom
   STICHTING EUROPEAN MYELOMA NETWORK
      2021   Phase 2   EUCTR2020-004001-32-IT   France;Germany;Greece;Italy;Netherlands;United Kingdom
   Stichting European Myeloma Network
      2021   Phase 2   NCT04617925   France;Germany;Greece;Italy;Netherlands;United Kingdom
   Stichting European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-DE   France;Germany;Greece;Italy;Netherlands;United Kingdom
Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks AS determined BY part 1 recommended dosages
   University of Texas Southwestern Medical Center
      2024   Phase 1/Phase 2   NCT05145816   United States
Bendamustine
   Columbia University
      2013   Phase 2   NCT01222260   United States
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Betamethasone
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Biopsy
   National Center for Global Health and Medicine
      2010   -   JPRN-UMIN000012319   Japan
Biospecimen collection
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Birtamimab
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Prothena Biosciences Limited
      2023   Phase 3   EUCTR2021-000037-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PT   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-HU   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-GR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-ES   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
   Prothena Biosciences Ltd.
      2021   Phase 3   NCT04973137   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Blood samples FOR ANTI-drug antibodies
   Akcea Therapeutics
      2021   Phase 4   NCT04306510   Canada;United States
Blood samples FOR immunoglobulins
   Akcea Therapeutics
      2021   Phase 4   NCT04306510   Canada;United States
Blood samples FOR inflammatory markers
   Akcea Therapeutics
      2021   Phase 4   NCT04306510   Canada;United States
Bmdex
   European Myeloma Network
      2011   Phase 3   NCT01277016   Italy
Bone marrow ablation with stem cell support
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
Bone marrow aspiration
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Bone marrow aspiration and biopsy
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Bone marrow biopsy
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Bortezomib
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Barbara Ann Karmanos Cancer Institute
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
      2007   Phase 2   NCT00520767   United States
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
      2009   Phase 2   NCT01083316   United States
      2008   Phase 2   NCT00790647   United States
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   Emory University
      2021   Phase 1   NCT04754945   United States
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
      2012   Phase 2   EUCTR2010-021445-42-BE   Belgium;Germany;Netherlands
      2011   Phase 2   EUCTR2010-021445-42-NL   Belgium;Germany;Netherlands
   JANSSEN-CILAG
      2005   -   EUCTR2004-004871-12-IT   Italy
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
   Jin Lu, MD
      2024   Phase 2   NCT06342466   China
      2024   -   NCT06192979   China
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
      2010   Phase 2   NCT01072773   United States
   Memorial Sloan Kettering Cancer Center
      2007   Phase 2   NCT00458822   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   National Cancer Institute (NCI)
      2010   Phase 3   NCT01078454   United States
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Peking University People's Hospital
      2024   -   NCT06627309   China
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   University College London
      2010   -   EUCTR2009-014906-33-GB   United Kingdom
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
   Zhi-Hong Liu, M.D.
      2011   -   NCT01273844   China
Bortezomib accord
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Bortezomib D-mannitol
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Bortezomib/dexamethasone (BD), followed BY autologous STC & maintenance bortezomib/dexamethasone
   Memorial Sloan Kettering Cancer Center
      2011   -   NCT01383759   United States
Busulfan
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
CAEL-101
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2019-004254-28-IT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-000713-32-NL   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-000713-32-CZ   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-000713-32-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-004254-28-NL   Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-004254-28-CZ   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-004254-28-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   NCT04504825   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-PL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-PL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04512235   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   NCT04304144   United States
      2020   Phase 3   EUCTR2020-000713-32-GR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2020-000713-32-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-GR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   Caelum Biosciences, Inc.
      2021   Phase 3   EUCTR2020-000713-32-IT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-GB   Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
Carboplatin
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
Carfilzomib
   University College, London
      2015   Phase 1/Phase 2   NCT02545907   United Kingdom
Carmustine
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
CC-4047
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
   OSPEDALE POLICLINICO S. MATTEO
      2012   -   EUCTR2011-001787-22-IT   Italy
CC-5013
   Mayo Clinic
      2005   Phase 2   NCT00166413   United States
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
Cetirizina dicloridrato
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Chemotherapy
   IRCCS Policlinico S. Matteo
      2015   Phase 2   NCT01531751   Italy
Chimeric fibril-reactive IGG1K monoclonal antibody 11-1f4
   Caelum Biosciences, Inc.
      2021   Phase 3   EUCTR2020-000713-32-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000713-32-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004254-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004254-28-GB   Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom;United States
Chimeric fibril-reactive monoclonal ANTI-body 11-1f4
   Alexion Pharmaceuticals, Inc.
      2014   Phase 1   NCT02245867   United States
CHX A-dtpa ANTI-CD66 antibody
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
CHX-A-DTPA-ANTI-CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Ciltacabtagene autoleucel
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Cisplatin
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
CM-336 bcma/CD3 bispecific antibody
   Institute of Hematology & Blood Diseases Hospital, China
      2025   -   NCT06769555   -
Coagadex
   Kedrion S.p.A.
      2025   Phase 3   NCT06963216   -
Computed tomography
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Current treatment OF AL-CM
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2021   -   NCT04924998   China
Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence IN situ hybridization (fish) assay
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
Cyclophosphamide
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
   Emory University
      2021   Phase 1   NCT04754945   United States
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   Guangdong Provincial People's Hospital
      2020   Phase 4   NCT04612582   China
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   IRCCS Policlinico S. Matteo
      2008   Phase 2   NCT00607581   Italy
   Icahn School of Medicine at Mount Sinai
      2017   Phase 1/Phase 2   NCT03236792   United States
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
   Mayo Clinic
      2010   Phase 2   NCT01072773   United States
      2007   Phase 2   NCT00564889   United States
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
   PETHEMA Foundation
      2010   Phase 2   NCT01194791   Spain
   Peking University People's Hospital
      2024   -   NCT06627309   China
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Cyclophosphamide, bortezomib, and dexamethasone (cybord) regimen
   Alexion Pharmaceuticals, Inc.
      2021   Phase 3   NCT04504825   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04512235   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
Cyclosporine
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
D-glucitol
   Pfizer Inc.
      2009   -   EUCTR2009-011535-12-PT   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
      2009   -   EUCTR2009-011535-12-DE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Dapagliflozin
   Barbara Ann Karmanos Cancer Institute
      2024   Phase 2   NCT06420167   United States
Dara IV
   Peking University People's Hospital
      2024   -   NCT06627309   China
Dara SC
   Peking University People's Hospital
      2024   -   NCT06627309   China
Daratumumab
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
   Boston Medical Center
      2017   Phase 1/Phase 2   NCT02841033   United States
   CHU DE LIMOGES
      2017   Phase 2   EUCTR2016-000287-42-IT   France;Italy
   CHU de Limoges
      2016   Phase 2   EUCTR2016-000287-42-FR   France
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2021   Phase 2   EUCTR2019-001962-13-IT   Italy
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-IT   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
   Jin Lu, MD
      2024   -   NCT06192979   China
   M.D. Anderson Cancer Center
      2018   Phase 1   NCT03283917   United States
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   University Hospital, Limoges
      2016   Phase 2   NCT02816476   France;Italy
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
Daratumumab and hyaluronidase-fihj
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Daratumumab and pomalidomide
   Fondazione IRCCS Policlinico San Matteo di Pavia
      2021   Phase 2   NCT04895917   Italy
Daratumumab injection
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Daratumumab SC
   Weill Medical College of Cornell University
      2021   Phase 2   NCT04270175   United States
Daratumumab/daratumumab and hyaluronidase-fihj
   Yongyong MA
      2024   -   NCT06455748   China
Darzalex
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Dazarlex
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
Deaxamethasone
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
Decadron
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
Desametasone
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Desametasone sodio fosfato
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Dexametasone
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Dexamethason
   European Myeloma Network
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
Dexamethasone
   Alexion Pharmaceuticals, Inc.
      2020   Phase 2   NCT04304144   United States
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
      2007   Phase 2   NCT00520767   United States
   Boston Medical Center
      2012   Phase 1/Phase 2   NCT01570387   United States
      2009   Phase 2   NCT01083316   United States
      2008   Phase 2   NCT00679367   United States
   Columbia University
      2013   Phase 2   NCT01222260   United States
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022395-31-SE   Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   Emory University
      2021   Phase 1   NCT04754945   United States
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   IRCCS Policlinico S. Matteo
      2008   Phase 2   NCT00607581   Italy
   Icahn School of Medicine at Mount Sinai
      2017   Phase 1/Phase 2   NCT03236792   United States
   Janssen Pharmaceutical K.K.
      2018   Phase 4   JPRN-jRCT2080223872   Asia except Japan;Europe;Japan;North America
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
   Jin Lu, MD
      2024   Phase 2   NCT06342466   China
      2024   -   NCT06192979   China
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
   M.D. Anderson Cancer Center
      2018   Phase 1   NCT03283917   United States
      2014   Phase 1   NCT01807286   United States
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
      2010   Phase 2   NCT01072773   United States
      2007   Phase 2   NCT00564889   United States
      2005   Phase 3   NCT00477971   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03618537   United States
      2007   Phase 2   NCT00458822   United States
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
      2010   Phase 3   NCT01078454   United States
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
   Oncopeptides AB
      2020   Phase 1/Phase 2   NCT04115956   Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   PETHEMA Foundation
      2010   Phase 2   NCT01194791   Spain
   Peking University People's Hospital
      2024   -   NCT06627309   China
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
      1996   Phase 2   NCT00002849   United States
   Stanford University
      2009   -   NCT00890552   United States
   Tufts Medical Center
      2017   Phase 1   NCT03000660   United States
   University College, London
      2015   Phase 1/Phase 2   NCT02545907   United Kingdom
   University Hospital, Limoges
      2000   Phase 3   NCT00344526   France
   Vaishali Sanchorawala
      2004   Phase 2   NCT00091260   United States
   Weill Medical College of Cornell University
      2021   Early Phase 1   NCT04984330   United States
      2021   Phase 2   NCT04270175   United States
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
   Yongyong MA
      2024   -   NCT06455748   China
Dexamethasone 4 MG jenapharm
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Dexamethasone krka
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Dexamethasone oral, 10 MG
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Dexamethasone oral, 20 MG
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Dexamethasone sodium sulfate
   OSPEDALE POLICLINICO S. MATTEO
      2012   -   EUCTR2011-001787-22-IT   Italy
Dexamethasone, 40 MG
   Janssen Research & Development, LLC
      2017   Phase 3   NCT03201965   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
Dexaton
   European Myeloma Network
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
Dezamizumab
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Diflunisal
   Boston University
      2006   Phase 2/Phase 3   NCT00294671   Italy;Japan;Portugal;Sweden;United Kingdom;United States
   Department of Neurology, Faculty of Life Sciences, Kumamoto University
      2012   Phase 3   JPRN-UMIN000008396   Japan
   John L. Berk
      2010   -   EUCTR2006-001066-16-GB   Italy;Sweden;United Kingdom
   John L. Berk, M.D.
      2007   -   EUCTR2006-001066-16-SE   Italy;Sweden;United Kingdom
   Shinshu University
      2009   -   JPRN-UMIN000001825   Japan
Diuretics (plus antiarrhythmic drugs, I.E. amiodarone, IN case OF complex ventricular arrhythmias) plus egcg
   IRCCS Policlinico S. Matteo
      2012   Phase 2   NCT01511263   Italy
DNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Dolobid
   Boston University- The Amyloid Treatment and Research Program
      2007   -   EUCTR2006-001066-16-IT   Italy;Sweden;United Kingdom
   John L. Berk
      2010   -   EUCTR2006-001066-16-GB   Italy;Sweden;United Kingdom
   John L. Berk, M.D.
      2007   -   EUCTR2006-001066-16-SE   Italy;Sweden;United Kingdom
Donor lymphocytes
   Fred Hutchinson Cancer Research Center
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
Doxiciclina
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2018   Phase 2   EUCTR2017-002210-31-IT   Germany;Italy
Doxorubicin
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Doxycycline
   Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
      2019   Phase 2;Phase 3   EUCTR2017-002210-31-DE   Canada;Germany;Italy;Turkey
   Fondazione IRCCS Policlinico San Matteo di Pavia
      2019   Phase 2/Phase 3   NCT03474458   Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom
   Medical College of Wisconsin
      2014   Phase 2   NCT02207556   United States
Doxyhexal® tabs 100 MG tabletten
   Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo
      2019   Phase 2;Phase 3   EUCTR2017-002210-31-DE   Canada;Germany;Italy;Turkey
Echocardiography
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Echocardiography test
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Egcg
   Florian Michel
      2013   Phase 2   NCT02015312   Germany
Elotuzumab
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
Elranatamab
   Brigham and Women's Hospital
      2024   Phase 1/Phase 2   NCT06569147   United States
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Enbrel
   The Cleveland Clinic
      2001   Phase 2   NCT00224393   -
Endoxan
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Epigallocatechin-3-gallate
   Florian Michel
      2013   Phase 2   NCT02015312   Germany
Eplontersen
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-001427-40-IT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
   Ionis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-001427-40-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-FR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-ES   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-CY   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
Etoposide
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Filgrastim
   Boston Medical Center
      2008   Phase 2   NCT00790647   United States
      2001   Phase 2   NCT00075608   United States
      2000   Phase 2   NCT00075621   United States
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Mayo Clinic
      2005   Phase 3   NCT00477971   United States
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
Fish assay
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Flow cytometry
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Fludarabine phosphate
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
Fortecortin
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
   European Myeloma Network
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
Foscarnet sodium
   City of Hope Medical Center
      2010   -   NCT01199562   United States
FX-1006A
   FOLDRX PHARMACEUTICALS, INC.
      2010   Phase 3   EUCTR2009-011535-12-IT   France;Germany;Italy;Portugal;Sweden
      2008   -   EUCTR2007-006791-12-IT   France;Germany;Italy
   FoldRx Pharmaceuticals Limited
      2009   -   EUCTR2008-001262-87-DE   France;Germany;Portugal;Sweden
      2008   -   EUCTR2008-001262-87-SE   France;Germany;Portugal;Sweden
      2007   -   EUCTR2006-002792-41-DE   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-SE   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001262-87-PT   France;Germany;Portugal;Sweden
      2008   Phase 2;Phase 3   EUCTR2008-001262-87-FR   France;Germany;Portugal;Sweden
      2007   Phase 2;Phase 3   EUCTR2006-002792-41-GB   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-PT   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Ltd.
      2009   Phase 3   EUCTR2009-011535-12-FR   France;Germany;Italy;Portugal;Sweden
   Pfizer
      2008   Phase 2/Phase 3   NCT00791492   Argentina;Brazil;France;Germany;Portugal;Sweden
      2007   Phase 2/Phase 3   NCT00409175   Argentina;Brazil;France;Germany;Portugal;Spain;Sweden;United Kingdom;United States
   Pfizer Inc.
      2009   -   EUCTR2009-011535-12-PT   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
      2009   -   EUCTR2009-011535-12-DE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Ganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Granulocyte colony stimulating factor
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
Green TEA
   Japanese Red Cross Medical Center, Division of Hematology
      2015   Phase 2   JPRN-UMIN000019732   Japan
GSK2315698
   GlaxoSmithKline
      2013   Phase 1   NCT01777243   United Kingdom
      2011   Phase 1   NCT01406314   United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
GSK2398852
   GlaxoSmithKline
      2013   Phase 1   NCT01777243   United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
GSK2857916
   European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-NL   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-GR   France;Germany;Greece;Italy;Netherlands;United Kingdom
      2021   Phase 2   EUCTR2020-004001-32-FR   France;Germany;Greece;Italy;Netherlands;United Kingdom
   STICHTING EUROPEAN MYELOMA NETWORK
      2021   Phase 2   EUCTR2020-004001-32-IT   France;Germany;Greece;Italy;Netherlands;United Kingdom
   Stichting European Myeloma Network – EMN
      2021   Phase 2   EUCTR2020-004001-32-DE   France;Germany;Greece;Italy;Netherlands;United Kingdom
GSK3039294
   GlaxoSmithKline
      2016   Phase 1   NCT02603172   United Kingdom
H02ab02
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
H02ab02 desametasone
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
High CUT-OFF hemodialysis
   IRCCS Policlinico S. Matteo
      2015   Phase 2   NCT01531751   Italy
Human transthyretin antisense oligonucleotide
   Ionis Pharmaceuticals, Inc
      2015   Phase 3   EUCTR2013-004561-13-GB   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2013-004561-13-DE   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-005115-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005115-13-ES   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-PT   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-GB   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-DE   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-GB   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-FR   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc
      2015   -   EUCTR2013-004561-13-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-FR   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc.
      2015   -   EUCTR2012-001831-30-BG   Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States
      2014   Phase 2;Phase 3   EUCTR2012-001831-30-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-IT   Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
Humanized IGG1 kappa antiamyloid
   Prothena Biosciences Limited
      2023   Phase 3   EUCTR2021-000037-14-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-IE   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000037-14-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PT   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-PL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-HU   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-GR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-FR   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-ES   Australia;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DK   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000037-14-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Türkiye;United Kingdom;United States
Humanized IGG1, kappa ANTI-serum amyloid A and ANTI-AL amyloid antibody
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2017   Phase 2   EUCTR2016-000489-50-IT   Italy
   Prothena Therapeutics Limited
      2018   Phase 2   EUCTR2016-004664-18-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GR   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-ES   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-ES   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
Humax-CD38
   CHU DE LIMOGES
      2017   Phase 2   EUCTR2016-000287-42-IT   France;Italy
   CHU de Limoges
      2016   Phase 2   EUCTR2016-000287-42-FR   France
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   JANSSEN CILAG INTERNATIONAL NV
      2018   Phase 3   EUCTR2016-001737-27-IT   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
Humax-CD38, 3003-005
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
Hyaluronidase
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
I124-AT01 only
   Attralus, Inc.
      2021   Phase 2   NCT05235269   United States
Ibrutinib
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
Idecabtagene vicleucel
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Imatinib mesylate
   National Cancer Institute (NCI)
      2001   Phase 1   NCT00025415   United States
Imnovid
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2021   Phase 2   EUCTR2019-001962-13-IT   Italy
Imnovid 1 MG
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Imnovid 2 MG
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Imnovid 4 MG
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Indium 111-radiolabelled ANTI-CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Indium­ 111 ­labelled anti­-CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Infection prophylaxis and management
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Inoserten
   Ionis Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
Inotersen
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001698-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-CY   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2018   -   NCT03400098   United States
      2018   Phase 3   EUCTR2017-005115-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   NCT02175004   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2/Phase 3   NCT01737398   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-GB   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-FR   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
Iodine
   University of Tennessee Graduate School of Medicine
      2022   Phase 2   NCT05968846   United States
ION-682884
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-001427-40-IT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
   Ionis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-001427-40-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-FR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-ES   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2022   Phase 3   EUCTR2021-001427-40-CY   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
      2021   Phase 3   EUCTR2019-001698-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-CY   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
Isatuximab
   Emory University
      2021   Phase 1   NCT04754945   United States
   Intergroupe Francophone du Myelome
      2022   Phase 2   NCT05066607   France
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
   SWOG Cancer Research Network
      2018   Phase 2   NCT03499808   United States
Isis 420915
   Ionis Pharmaceuticals, Inc
      2015   Phase 3   EUCTR2013-004561-13-GB   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2013-004561-13-DE   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001698-10-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-SE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-PT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GR   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-DE   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Italy;Netherlands;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom
      2020   Phase 3   EUCTR2019-001698-10-CY   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;China;Colombia;Cyprus;Estonia;France;Germany;Greece;Ireland;Israel;Italy;Japan;Korea, Democratic People's Republic of;Latvia;Malaysia;Mexico;Netherlands;New Zealand;Portugal;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom
      2018   Phase 3   EUCTR2017-005115-13-PT   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-005115-13-ES   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-PT   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-GB   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-DE   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-GB   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-005115-13-FR   Argentina;Brazil;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc
      2015   -   EUCTR2013-004561-13-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;New Zealand;Portugal;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004561-13-FR   Argentina;Brazil;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
   Isis Pharmaceuticals, Inc.
      2015   -   EUCTR2012-001831-30-BG   Argentina;Australia;Brazil;Bulgaria;France;Germany;Italy;Mexico;Portugal;Spain;United Kingdom;United States
      2014   Phase 2;Phase 3   EUCTR2012-001831-30-ES   Argentina;Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
      2013   Phase 2;Phase 3   EUCTR2012-001831-30-IT   Brazil;Bulgaria;France;Germany;Italy;Portugal;Spain;United Kingdom;United States
Isis 420915/GSK 299872
   Brigham and Women's Hospital
      2016   Phase 2   NCT02627820   -
Ixazomib
   Icahn School of Medicine at Mount Sinai
      2017   Phase 1/Phase 2   NCT03236792   United States
   M.D. Anderson Cancer Center
      2018   Phase 1   NCT03283917   United States
   Memorial Sloan Kettering Cancer Center
      2018   Phase 2   NCT03618537   United States
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Ixazomib citrate
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
JNJ 54767414
   JANSSEN CILAG INTERNATIONAL NV
      2018   Phase 3   EUCTR2016-001737-27-IT   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
   Janssen-Cilag International N.V.
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
JNJ-54767414
   European Myeloma Network
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
JNJ-79635322
   Janssen Research & Development, LLC
      2022   Phase 1   NCT05652335   Belgium;France;Japan;Netherlands;Spain;United Kingdom;United States
Kineret*SC 7SIR 100MG 0,67ML
   ISTITUTO GIANNINA GASLINI
      2006   -   EUCTR2006-001927-20-IT   Italy
KP-2541
   K-Group Alpha, Inc
      2023   Phase 1;Phase 2   EUCTR2021-003008-42-CY   Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;United Kingdom;United States
   K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
      2021   Phase 1;Phase 2   EUCTR2021-003008-42-GR   Australia;Cyprus;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;United States
L01aa03
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
Laboratory biomarker analysis
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
      2007   Phase 2   NCT00520767   United States
   City of Hope Medical Center
      2010   -   NCT01199562   United States
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
   Mayo Clinic
      2018   Phase 2   NCT03130348   United States
   National Cancer Institute (NCI)
      2009   Phase 1   NCT00890747   United States
   SWOG Cancer Research Network
      2018   Phase 2   NCT03499808   United States
Lenalidomide
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
   Boston Medical Center
      2008   Phase 2   NCT00679367   United States
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Heidelberg University
      2009   Phase 2   NCT00883623   Germany
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   IRCCS Policlinico S. Matteo
      2008   Phase 2   NCT00607581   Italy
   Mayo Clinic
      2007   Phase 2   NCT00564889   United States
   PETHEMA Foundation
      2010   Phase 2   NCT01194791   Spain
   Stanford University
      2009   -   NCT00890552   United States
   Vaishali Sanchorawala
      2004   Phase 2   NCT00091260   United States
Lenalidomide 25MG
   Seoul National University Hospital
      2019   Phase 3   NCT04298372   Korea, Republic of
Lenalidomide, dexamethasone and cyclophosphamide
   University of Athens
      2008   Phase 1/Phase 2   NCT00981708   Greece
Lenogastrim
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
Leukine
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Linvoseltamab
   Regeneron Pharmaceuticals
      2024   Phase 1/Phase 2   NCT06292780   Korea, Republic of;Spain;United Kingdom;United States
Live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with bortezomib+dexamethasone/bortezomib+dexamethasone+daratumumab/single daratumumab
   Air Force Military Medical University, China
      2023   Phase 3   NCT05776940   -
Magnetic resonance imaging
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Management OF therapy complications
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Melflufen
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1/Phase 2   NCT04115956   Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Melphalan
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
      2009   Phase 2   NCT01083316   United States
      2008   Phase 2   NCT00790647   United States
      2008   Phase 2   NCT00679367   United States
      2001   Phase 2   NCT00075608   United States
      2000   Phase 2   NCT00075621   United States
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022395-31-SE   Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   European Myeloma Network
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Japan Community Health care Organization Kyoto kuramaguchi Medical Center, Department of Hematology
      2011   Phase 1,2   JPRN-UMIN000006604   Japan
   Joint UCLH and UCL Biomedical Research Unit
      2007   Phase 2;Phase 3   EUCTR2006-006395-37-GB   United Kingdom
   M.D. Anderson Cancer Center
      2014   Phase 1   NCT01807286   United States
   Mayo Clinic
      2005   Phase 3   NCT00477971   United States
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   Nanjing University School of Medicine
      2007   Phase 3   NCT01998503   China
   National Cancer Institute (NCI)
      2010   Phase 3   NCT01078454   United States
   Oncopeptides AB
      2020   Phase 1/Phase 2   NCT04115956   Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
   Stanford University
      2009   -   NCT00890552   United States
   University Hospital, Limoges
      2000   Phase 3   NCT00344526   France
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Melphalan fulfenamide hydrochloride
   ONCOPEPTIDES AB
      2019   Phase 1;Phase 2   EUCTR2018-002761-19-IT   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
   Oncopeptides AB
      2020   Phase 1;Phase 2   EUCTR2018-002761-19-ES   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2018-002761-19-DE   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-PL   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-NO   Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-GR   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002761-19-CZ   Czech Republic;France;Germany;Greece;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
Melphalan, thalidomide and dexamethasone
   FDA Office of Orphan Products Development
      2002   Phase 2   NCT01527032   -
Microarray analysis
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
Miridesap
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Monitor
   Marianna Fontana
      2021   -   NCT04856267   United Kingdom
Mycophenolate mofetil
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium
   FoldRx Pharmaceuticals Limited
      2009   -   EUCTR2008-001262-87-DE   France;Germany;Portugal;Sweden
      2008   -   EUCTR2008-001262-87-SE   France;Germany;Portugal;Sweden
      2007   -   EUCTR2006-002792-41-DE   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-SE   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001262-87-PT   France;Germany;Portugal;Sweden
      2008   Phase 2;Phase 3   EUCTR2008-001262-87-FR   France;Germany;Portugal;Sweden
      2007   Phase 2;Phase 3   EUCTR2006-002792-41-GB   Germany;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002792-41-PT   Germany;Portugal;Spain;Sweden;United Kingdom
   FoldRx Pharmaceuticals, Ltd.
      2009   Phase 3   EUCTR2009-011535-12-FR   France;Germany;Italy;Portugal;Sweden
NEOD001
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2017   Phase 2   EUCTR2016-000489-50-IT   Italy
   Prothena Therapeutics Limited
      2018   Phase 2   EUCTR2016-004664-18-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GR   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-ES   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004664-18-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-GB   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-ES   Austria;France;Germany;Greece;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-DE   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004318-14-AT   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
   Prothena Therapeutics Ltd.
      2017   Phase 2   NCT03154047   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   NCT02632786   Australia;Austria;France;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2016   Phase 2   NCT02613182   United States
      2015   Phase 3   NCT02312206   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Neupogen
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
Nexiguran ziclumeran
   Intellia Therapeutics
      2024   Phase 3   NCT06672237   Argentina;Australia;Brazil;New Zealand;Singapore;Taiwan
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
NTLA-2001
   Intellia Therapeutics
      2020   Phase 1   NCT04601051   France;New Zealand;Sweden;United Kingdom
NXC-201 CAR-T
   Nexcella Inc.
      2024   Phase 1   NCT06097832   United States
Onpattro
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Oral drops solution
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
Paracetamolo
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Patisiran
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals
      2019   Phase 3   NCT03759379   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224769   Asia except Japan;Europe;Japan;North America;Oceania;South America
Pegylated recombinant human hyaluronidase PH20
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
Peripheral blood stem cell transplantation
   Eastern Cooperative Oncology Group
      2004   Phase 1   NCT00052884   United States
      1998   Phase 2   NCT00003353   United States
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
PF-06291826-83/FX-1006A
   Pfizer Inc.
      2009   Phase 3   EUCTR2009-011535-12-SE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Pharmacological study
   Barbara Ann Karmanos Cancer Institute
      2017   Phase 2   NCT03252600   United States
   National Cancer Institute (NCI)
      2009   Phase 1   NCT00890747   United States
      2001   Phase 1   NCT00030381   United States
      2001   Phase 1   NCT00025415   United States
Polymerase chain reaction
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Pomalidomide
   Barbara Ann Karmanos Cancer Institute
      2013   Phase 1   NCT01728259   Canada;New Zealand;United States
   Boston Medical Center
      2012   Phase 1/Phase 2   NCT01570387   United States
   FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
      2021   Phase 2   EUCTR2019-001962-13-IT   Italy
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
   Jin Lu, MD
      2024   Phase 2   NCT06342466   China
   M.D. Anderson Cancer Center
      2014   Phase 1   NCT01807286   United States
   OSPEDALE POLICLINICO S. MATTEO
      2012   -   EUCTR2011-001787-22-IT   Italy
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
   Weill Medical College of Cornell University
      2021   Phase 2   NCT04270175   United States
   Yongyong MA
      2024   -   NCT06455748   China
Pomalidomide 4 MG
   Nanjing University School of Medicine
      2023   -   NCT06376214   China
Pomalidomide and dexamethasone
   IRCCS Policlinico S. Matteo
      2012   Phase 2   NCT01510613   Italy
Positron emission tomography
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Prednisone
   West China Hospital of Sichuan University
      2025   Phase 4   ChiCTR2500103075   China
Propylene glycol-free melphalan hydrochloride
   Boston Medical Center
      2018   Phase 2   NCT02994784   United States
Protein expression analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Psyllium
   Centre Hospitalier Universitaire de Nice
      2023   -   NCT04695340   France
Pyrrolidine
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Pyrrolidone
   GlaxoSmithKline Research & Development Ltd
      2016   Phase 2   EUCTR2016-000276-23-GB   United Kingdom;United States
Quality-OF-life assessment
   Barbara Ann Karmanos Cancer Institute
      2007   Phase 2   NCT00520767   United States
Questionnaire administration
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
Questionnaires
   M.D. Anderson Cancer Center
      2014   Phase 1   NCT01807286   United States
Ranidil - 50 MG/5 ML soluzione iniettabile PER USO endovenoso 10 fiale
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Ranitidina
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Recombinant human hyaluronidase
   JANSSEN CILAG INTERNATIONAL NV
      2022   Phase 2   EUCTR2021-002639-48-IT   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
   Janssen-Cilag International N.V.
      2022   Phase 2   EUCTR2021-002639-48-NL   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-FR   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-ES   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-002639-48-DE   Canada;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-SE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-PL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-NL   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-HU   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GR   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-GB   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-ES   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DK   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-DE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2016-001737-27-BE   Australia;Belgium;Brazil;Canada;China;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Spain;Sweden;Türkiye;United Kingdom;United States
Recombinant interferon alfa
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Southwest Oncology Group
      1996   Phase 2   NCT00002849   United States
Revlimid
   GMIHO mbH
      2008   -   EUCTR2008-001405-41-DE   Germany
   Hellenic Oncology Cooperative Group
      2007   -   EUCTR2006-007082-36-GR   Greece
   OSPEDALE POLICLINICO S. MATTEO
      2008   -   EUCTR2007-006037-13-IT   Italy
Revusiran
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-005333-49-GB   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-SE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-DE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003835-20-BE   Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-003835-20-GB   Belgium;Brazil;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
RNA analysis
   City of Hope Medical Center
      2010   -   NCT01199562   United States
SAR445514
   Sanofi
      2023   Phase 1/Phase 2   NCT05839626   Australia;Belgium;Czechia;Hungary;Italy;Spain;United Kingdom
SAR650984
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Sarclisa
   Intergroupe Francophone du Myélome
      2021   Phase 2   EUCTR2020-004333-20-FR   Australia;France
Sargramostim
   Herbert Irving Comprehensive Cancer Center
      1999   Phase 2   NCT00007995   United States
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Selinexor
   Weill Medical College of Cornell University
      2021   Early Phase 1   NCT04984330   United States
Siltuximab
   Memorial Sloan Kettering Cancer Center
      2017   Phase 2   NCT03315026   United States
Soldesam - 4 MG/ML soluzione iniettabile 3 fiale 1 ML
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
SOM0226
   SOM Biotech SL
      2014   Phase 1/Phase 2   NCT02191826   Spain
   SOM Innovation Biotech SL (SOM Biotech)
      2014   -   EUCTR2014-001586-27-ES   Spain
Standard OF care chemotherapy
   Nie Christie
      2023   Phase 3   JPRN-jRCT2031220037   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Poland;Portugal;Republic of Korea;Spain;Taiwan;Turkey;United Kingdom;United States
   Prothena Biosciences Ltd.
      2021   Phase 3   NCT04973137   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
Standard OF care therapy
   Fondazione IRCCS Policlinico San Matteo di Pavia
      2019   Phase 2/Phase 3   NCT03474458   Canada;France;Germany;Greece;Italy;Spain;Turkey;United Kingdom
Stem cell collection
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
Stem cell infusion
   Boston Medical Center
      2015   Phase 3   NCT02489500   United States
      2008   Phase 2   NCT00790647   United States
      2001   Phase 2   NCT00075608   United States
Stem cell isolation
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
STI-6129
   Sorrento Therapeutics, Inc.
      2023   Phase 1   NCT05692908   -
      2021   Phase 1/Phase 2   NCT04316442   United States
Sunitinib malate
   National Cancer Institute (NCI)
      2009   Phase 1   NCT00890747   United States
Survey administration
   SWOG Cancer Research Network
      2024   Phase 3   NCT06022939   United States
Tachipirina - 500 MG compresse10 compresse
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Tafamidis
   Pfizer
      2023   -   NCT05139680   United States
      2022   -   NCT05560555   Spain
      2011   Phase 3   NCT01435655   Japan
Tafamidis meglumine
   Pfizer Inc.
      2009   -   EUCTR2009-011535-12-PT   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
      2009   -   EUCTR2009-011535-12-DE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
   Pfizer Japan Inc.
      2011   Phase 3   JPRN-jRCT2080221636   -
Tafamidis meglumine 20 MG soft gelatin capsules
   Pfizer Inc.
      2009   Phase 3   EUCTR2009-011535-12-SE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
Talquetamab
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Tasmar
   SOM Innovation Biotech SL (SOM Biotech)
      2014   -   EUCTR2014-001586-27-ES   Spain
TEA extract
   Japanese Red Cross Medical Center, Division of Hematology
      2015   Phase 2   JPRN-UMIN000019732   Japan
Technetium-99M
   University of Tennessee Graduate School of Medicine
      2023   Phase 1   NCT05951816   United States
Teclistamab
   European Myeloma Network B.V.
      2025   Phase 2   NCT06649695   Australia;France;Germany;Greece;Italy;Netherlands
   Peking University People's Hospital
      2025   -   NCT06699394   China
   St. Olavs Hospital
      2025   -   NCT06855121   Norway
Thalidomide
   Guangdong General Hospital
      2017   -   ChiCTR-IPR-17012637   China
   Guangdong Provincial People's Hospital
      2020   Phase 4   NCT04612582   China
   Memorial Sloan Kettering Cancer Center.
      2002   Phase 2   NCT00089167   United States
   People's Hospital, Beijing University
      2016   -   ChiCTR-IPR-16008422   China
   Southwest Oncology Group
      2004   Phase 2   NCT00064337   United States
   University College, London
      2015   Phase 1/Phase 2   NCT02545907   United Kingdom
   Yogesh Jethava
      2013   Phase 2   NCT01849783   United States
Thiotepa
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
TNB-383B
   Satomi Natsuko
      2024   Phase 1   JPRN-jRCT2071230131   -
Tolcapone
   SOM Innovation Biotech SL (SOM Biotech)
      2014   -   EUCTR2014-001586-27-ES   Spain
Total-body irradiation
   Fred Hutchinson Cancer Research Center
      2000   -   NCT00014235   Germany;Italy;United States
      2000   Phase 1/Phase 2   NCT00006251   Germany;Italy;United States
      1999   -   NCT00112593   United States
   Roswell Park Cancer Institute
      2006   -   NCT00536601   United States
Transabdominal ultrasound
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Valganciclovir
   City of Hope Medical Center
      2010   -   NCT01199562   United States
Velcade
   E.M.N. - EUROPEAN MYELOMA NETWORK
      2013   Phase 3   EUCTR2010-022395-31-CZ   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom;United States
      2012   -   EUCTR2010-022395-31-ES   Denmark;France;Germany;Greece;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-022395-31-SE   Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2010-022395-31-DK   Czech Republic;Denmark;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2010-022395-31-IT   Czech Republic;Denmark;Germany;Greece;Italy;Spain;Sweden;United Kingdom
   European Myeloma Network
      2020   Phase 2   EUCTR2018-004333-33-FR   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-NL   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-IT   France;Greece;Italy;Netherlands
      2019   Phase 2   EUCTR2018-004333-33-GR   France;Greece;Italy;Netherlands
      2012   -   EUCTR2010-022395-31-GR   Australia;Denmark;Greece;Italy;Spain;Sweden;United Kingdom
      2012   Phase 3   EUCTR2010-022395-31-DE   Czech Republic;Denmark;France;Germany;Greece;Italy;Netherlands;Spain;Sweden;United Kingdom
   HOVON Foundation
      2012   Phase 3   EUCTR2010-021445-42-DE   Belgium;Germany;Netherlands
      2012   Phase 2   EUCTR2010-021445-42-BE   Belgium;Germany;Netherlands
      2011   Phase 2   EUCTR2010-021445-42-NL   Belgium;Germany;Netherlands
   University College London
      2010   -   EUCTR2009-014906-33-GB   United Kingdom
   Warsaw Medical University/ Warszawski Uniwersytet Medyczny
      2023   Phase 2   EUCTR2021-005769-42-PL   Poland
Velcade*1FL 3,5MG
   JANSSEN-CILAG
      2005   -   EUCTR2004-004871-12-IT   Italy
Venetoclax
   Alfred Chung, MD
      2024   Phase 1/Phase 2   NCT05486481   United States
   Jin Lu, MD
      2024   -   NCT06192979   China
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
   Tufts Medical Center
      2017   Phase 1   NCT03000660   United States
Venetoclax MTD with dexamethasone
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Venetoclax oral tablet, 200 MG
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Venetoclax oral tablet, 400 MG
   Rajshekhar Chakraborty, MD
      2022   Phase 1/Phase 2   NCT05451771   United States
Vitamina A
   IONIS PHARMACEUTICALS, INC.
      2022   Phase 3   EUCTR2021-001427-40-IT   Argentina;Australia;Brazil;Canada;Cyprus;France;Germany;Italy;New Zealand;Portugal;Spain;Sweden;Taiwan;Turkey;United States
Vutrisiran
   ALNYLAM PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-002098-23-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   Alnylam Pharmaceuticals
      2019   Phase 3   NCT03759379   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Alnylam Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-002098-23-PT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-CY   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002098-23-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Cyprus;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Portugal;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
   CMIC Co., Ltd.
      2019   Phase 3   JPRN-jRCT2080224769   Asia except Japan;Europe;Japan;North America;Oceania;South America
Vyndaqel
   Pfizer
      2014   -   NCT02146378   -
Vyndaqel 20MG soft capsule
   Pfizer Inc.
      2009   Phase 3   EUCTR2009-011535-12-SE   Argentina;Brazil;France;Germany;Italy;Portugal;Sweden;United States
X-RAY imaging
   Mayo Clinic
      2023   Phase 2   NCT05898646   United States
   National Cancer Institute (NCI)
      2022   Phase 1   NCT04847453   United States
Yttrium-90 radiolabelled ANTI-CD66 antibody
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Yttrium­90 radiolabelled anti­CD66
   University Southampton Hospital NHS Foundation Trust
      2015   -   EUCTR2015-002231-18-GB   United Kingdom
Zirtec
   Prothena Biosciences Limited
      2022   Phase 3   EUCTR2021-000037-14-IT   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Spain;Taiwan;Turkey;United Kingdom;United States
ZN-D5
   K-Group Alpha, Inc
      2023   Phase 1;Phase 2   EUCTR2021-003008-42-CY   Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;United Kingdom;United States
   K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
      2021   Phase 1/Phase 2   NCT05199337   Australia;Cyprus;Greece;Israel;Italy;Spain;United States
      2021   Phase 1;Phase 2   EUCTR2021-003008-42-GR   Australia;Cyprus;France;Germany;Greece;Israel;Italy;Korea, Republic of;Netherlands;Poland;United States
   Zentalis Pharmaceuticals
      2022   Phase 1;Phase 2   EUCTR2021-003008-42-IT   Australia;Brazil;Canada;Cyprus;France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States